‘I am very happy with the results that have been achieved thanks to this device I’m already planning on this new technology in the treatment of three other patients of mine We enormous progress in the field of pediatric cardiology. Especially in the treatment of Kawasaki disease, ‘said Dr. Nagib Dahdah levitra prix levitraprix.net . Its Faculty of Medicine includes over 4 000 students and is based on a solid hospital network with two major teaching hospitals and thirteen affiliated hospitals and institutions. Through its Reseau Universitaire Integre de Sante , the Faculty of Medicine for the health care of 40 percent of the Quebec population.


Bevasiranib is a first – in-class small interfering RNA develops drugs in order to genes that to bring prepare vascular endothelial growth factor silence of believed the largely responsible for of vision loss wet AMD. Bevasiranib represent the first therapeutic to the Nobel Prize-winning RNA interference technology is to to the point 3 of the clinical trials phase. Move ‘This first-ever Phase 3 trial of an agent RNAi technology is is a major milestone this new field We pride the capacity the ability out of our clinical group of success this innovative connection of the development has fast and cost effective. ‘said Philip Frost, chairman and CEO of OPKO Health. ‘Currently, wet AMD patients subjected intravitreal injections every four weeks a vision the vision for receive benefits of Lucentis, of the burden potential ability of bevasiranib similar results, similar results, while the less frequent injections would be an important advantage for these patients that often only by restricted mobility. ‘.